Skip to content

Daily News

63°F
Friday, September 18th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

3.115 +0.045 (+1.47%)
Delayed Quote Updated: 3:59 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alterity Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alignment reached on key elements of ATH434 Phase 3 development program 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg doses 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.